doxorubicin hydrochloride

P3, N=156, Not yet recruiting, Ruijin Hospital

Additionally, the OHCC potentiated the antiproliferative effect of doxorubicin, as evidenced by a raised Bax/Bcl-2 ratio and caspase 9 content, and suppressed VEGF levels...The histopathological investigation supported the apoptotic and necrotic death of cancer cells. These findings suggest that HCCs represent a promising nanocarrier system for the targeted parenteral delivery of FEL in cancer therapy.

Compound 2c exhibited potent activity against the colon cancer cell line HCT116 with an IC₅₀ of 5.17 ± 0.48 μM and a selectivity index (SI) of ≈3.42, outperforming the positive control doxorubicin (DOX, SI ≈ 2.19)...In a mouse colon cancer graft model, compound 2c achieved a 49.70% tumor inhibition rate at a dose of 20 mg/kg, with no obvious abnormalities observed in major organs. In conclusion, 2c is an effective mitochondrial MTHFD2 inhibitor with potential to develop into a potent anti-colon cancer drug.

Centering this chemo-photodynamic-immunotherapeutic cascade on enhanced ROS, ID-TEX concurrently improves efficacy, reduces toxicity, and strengthens immune modulation, underscoring strong translational potential for precision OSCC therapy.

Furthermore, CDDO-Me did not compromise the antitumor efficacy of DOX/LAP in breast cancer cells. CDDO-Me protects against DOX/LAP-induced cardiotoxicity by stabilizing GPX4 and inhibiting ferroptosis, offering a promising therapeutic strategy that preserves cardiac function without interfering with chemotherapy.

This study provides valuable real-world insight into the clinical landscape of DLBCL in Saudi Arabia. Overall outcomes are consistent with international data, although older age and comorbidities remain associated with poorer prognosis. As advanced therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies become more available, further improvements in survival are expected. These findings underscore the need for a national lymphoma registry and continued investment in research infrastructure to guide evidence-based, personalized care.

Treatment with 40 mg/kg of baicalin restored these indicators to levels comparable to those in untreated mice, with effects similar to irbesartan (P<0.05). We concluded that baicalin demonstrated significant renoprotective effects in both in vivo and in vitro models of ADR-induced NS by regulating the TGF-β/Smad pathway and NLRP3 inflammasome, mitigating renal injury and inflammation. These results offer experimental support for the potential use of baicalin as a therapeutic agent for NS.

To define mechanisms of resistance, we performed single-cell RNA sequencing on orthotopic TNBC patient-derived xenografts during a cycle of treatment with doxorubicin and cyclophosphamide (AC). Thus, the up-regulation of C15ORF48 blunts ROS accumulation and induces resistance to chemotherapy in the basal cell subpopulations. Our findings identify C15ORF48 as a potential therapeutic target for overcoming AC resistance in TNBC.

DSS confers cardioprotection against DOX-induced injury by disrupting the vicious circle formed by ROS and JNK, which mediated impairment of mitochondrial quality control, attenuating oxidative stress, and reducing apoptosis. These findings highlight DSS as a promising therapeutic candidate for mitigating chemotherapy-associated cardiotoxicity.

The patient remained in complete remission 40 months after the completion of chemoradiotherapy and 51 months after the initial surgery. This case demonstrates that stereotactic radiotherapy combined with doxorubicin-ifosfamide chemotherapy can achieve durable tumor control in PIS-DICER1, suggesting a potential therapeutic option for this highly aggressive tumor.

Functional studies in DLBCL cell lines further confirmed that TAp73 enhances sensitivity to serum deprivation and doxorubicin, whereas ΔNp73 overexpression promotes survival and chemoresistance...Functional studies showed TAp73 sensitizes DLBCL cells to stress and chemotherapy, while ΔNp73 enhances resistance. These findings highlight ΔNp73 as a potential biomarker and therapeutic target in DLBCL.

P2, N=90, Completed, SkinJect, Inc. | Recruiting --> Completed | N=60 --> 90 | Trial completion date: Jun 2025 --> Mar 2026 | Trial primary completion date: Feb 2025 --> Mar 2026